Myeloproliferative neoplasm physical examination

	Myeloproliferative Neoplasm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating myeloproliferative neoplasm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myeloproliferative neoplasm physical examination On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myeloproliferative neoplasm physical examination All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myeloproliferative neoplasm physical examination
on Myeloproliferative neoplasm physical examination
Myeloproliferative neoplasm physical examination in the news
Blogs on Myeloproliferative neoplasm physical examination
Directions to Hospitals Treating Myeloproliferative neoplasm
Risk calculators and risk factors for Myeloproliferative neoplasm physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Patients with myeloproliferative neoplasm are usually well-appearing. Physical examination of patients with chronic myelogenous leukemia is usually remarkable for skin bruising , fever, splenomegaly, and lymphadenopathy.^[1]

Physical Examination

Common physical examination findings associated with myeloproliferative neoplasm include:^[1]^[2]^[3]

Appearance of the Patient

Patients are usually well-appearing

Vital Signs

Fever

Skin

HEENT

Decreased vision acuity

Neck

Lymphadenopathy

Lungs

Vesicular breath sounds
Wheezing

Chest

Axillary lymphadenopathy (usually painless)

Abdomen

Splenomegaly

Genitourinary

Inguinal lymphadenopathy (usually painless)
Scrotal swelling
Priapism

References

↑ ^1.0 ^1.1 Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). "Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia". Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.
↑ Tefferi A (2006). "Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era". Hematology Am Soc Hematol Educ Program: 240–245. PMID 17124067.
↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab

Template:WH Template:WS

[pmid25810569-1] 1.0 ^1.1 Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). "Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia". Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.

[Tefferi-2] Tefferi A (2006). "Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era". Hematology Am Soc Hematol Educ Program: 240–245. PMID 17124067.

[cancer.ca-3] Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/signs-and-symptoms/?region=ab

[1]

[2]

[3]